Novel Agent Reduces Seizures in Treatment-Resistant Epilepsy
04/05/2026
Introducción Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the
Aprobación de un nuevo parche de terapia hormonal genérico Recentemente, la FDA aprobó el primer genérico del sistema transdérmico de…
Read more →Introducción Investigational azetukalner met its primary endpoint of reducing focal onset seizure frequency across two doses, initial findings from the
Colorectal cancer prevention has been framed around a simple principle: find polyps early, remove them, and repeat colonoscopy to prevent
Introducción Cardiovascular protection with GLP-1 receptor agonists may benefit patients undergoing certain transcatheter procedures, according to two observational studies. When
Introducción The FDA has expanded the approval for teplizumab (Tzield), a biologic agent designed to delay the progression of preclinical
Diabetic Patient Incident A CMS inspection report described how a diabetic patient with dementia at Eastland Healthcare and Rehabilitation Center